Therapeutic Doses of Nonsteroidal Anti-Inflammatory Drugs Inhibit Osteosarcoma MG-63 Osteoblast-Like Cells Maturation, Viability, and Biomineralization Potential
Table 2
Percentage of expression (by flow cytometry) of different antigens expressed in MG63 cell line after 24 h of treatment with different anti-inflammatories, at doses of 1 and 10 M.
Treatment
Monoclonal antibodies
CD54
CD80
CD86
HLA-DR
%, SDa
%, SDa
%, SDa
%, SDa
Control
75.5 (0.83)
—
19.9 (0.83)
—
13.1 (0.20)
—
5.2 (0.26)
—
Metamizole 1 µM
97.7 (0.57)
17.6 (0.61)
10.1 (0.6)
4.13 (0.49)
Metamizole 10 µM
97.3 (0.2)
14.4 (1.24)
8.8 (0.1)
3.8 (0.36)
Dexketoprofen 1 µM
97 (0.8)
14.4 (1.24)
9.7 (1.05)
4.43 (0.75)
0.17
Dexketoprofen 10 µM
98.2 (0.15)
17 (2.36)
0.11
11.2 (0.96)
0.06
5.56 (1.74)
0.73
Ketorolac 1 µM
98.2 (0.17)
16.3 (2.13)
0.11
13.43 (4.38)
0.926
5.76 (1.77)
0.63
Ketorolac 10 µM
97.6 (0.1)
16.6 (2.13)
0.055
10.2 (0.45)
4.73 (0.58)
0.27
Acetylsalicylic acid 1 µM
98.1 (0.5)
18.8 (2.45)
0.51
11.8 (1.37)
0.24
5.06 (0.35)
0.627
Acetylsalicylic acid 10 µM
98.3 (0.36)
18.8 (0.45)
0.12
11.2 (1.49)
0.09
5.26 (0.46)
0.839
Standard deviation, significant differences . Bold values is the statistical significance.
